1 week Ago By ABMN Staff
Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL – Get Free Report ) insider Mark Lackner sold 4,411 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.
12, for a total transaction of $13,762.32. Following the transaction, the insider now owns 191,317 shares in the company, valued at $596,909.
04. This trade represents a 2.25 % decrease in their position.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Zentalis Pharmaceuticals Stock Up 8.0 % Shares of ZNTL stock opened at $3.
24 on Friday. The firm has a market cap of $230.90 million, a price-to-earnings ratio of -1.
30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc.
has a 52-week low of $2.66 and a 52-week high of $18.07.
The company’s 50 day moving average is $3.33 and its 200 day moving average is $3.51.
Zentalis Pharmaceuticals ( NASDAQ:ZNTL – Get Free Report ) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
92) by $0.36. Analysts anticipate that Zentalis Pharmaceuticals, Inc.
will post -2.48 EPS for the current fiscal year. Institutional Inflows and Outflows Wall Street Analyst Weigh In Several brokerages recently commented on ZNTL.
Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.
00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $20.
00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.
com, the company currently has an average rating of “Hold” and an average price target of $10.00. Check Out Our Latest Research Report on ZNTL Zentalis Pharmaceuticals Company Profile ( Get Free Report ) Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. Read More Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
